Actuate Therapeutics, Inc. announced that data on their investigational drug elraglusib, designed to treat advanced salivary gland carcinoma by ... and enhancing immune cell function in cancer ...

Signet cell cancer is a rare type of cancer that mostly starts in the glandular cells. It is also called signet ring cell cancer. Nearly 57 out of 100 (57%) of all signet cell cancers start in the ...

Papillary renal cell ... salivary gland tumors) The names may seem more complicated but it also means they're more precise, and that allows healthcare providers to be more precise in their evaluation ...

This paper investigates how isoform II of transcription factor RUNX2 promotes cell survival and proliferation in oral squamous cell carcinoma cell lines. The authors used gain and loss of function ...

There have been only 24 documented occurrences of the extremely uncommon giant cell tumour of the parotid gland. We report an additional case of a female patient in her late 40s who presented with a 2 ...

Skin cancers such as squamous cell carcinoma and melanoma can metastasize to lymph nodes in and near the bilateral parotid glands, and thus mimic a primary parotid tumor. Most salivary gland cancers ...

"Elraglusib with chemotherapy and immune priming represents a novel sequential therapy approach to treat advanced salivary cancers. We were encouraged by the response rate among the non-Adenoid Cystic ...

1State Key Laboratory of Oral and Maxillofacial Reconstruction and Regeneration, Key Laboratory of Oral Biomedicine Ministry of Education, Hubei Key Laboratory of Stomatology, School and Hospital of ...

The cells were incubated in a 5% CO 2, 37°C incubator for 3 h. Absorbance values at 450 nm were measured using a microplate reader to calculate cell viability. For each group, 100 μL of cell ...

University of the Western Cape, Bellville, South Africa.